Pills that rival biologics, weight-loss drugs paired with psoriasis treatment and a phase 3 win for a personalized mRNA ...

Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 3 study in first ...

For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of developments reported during 2026 is providing new reasons for ...

This article was generated by AI. It does not contain any opinions or views from Imamura.How is the information for this article collected?There are four tools involved: Reuters, AP, and BBC ...

Reinsurance Group of America upgraded to Buy after strong underwriting and investment returns. See here for a detailed ...

Bayer shares close at EUR 42.95 as FDA accepts Kerendia review, but a US appeals court refuses to dismiss Roundup lawsuits ...

Psychedelics show promise for depression and anxiety. Federal support is growing, but drugs are advancing at different speeds ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Phase 3 randomized-withdrawal data in pediatrics indicated relapse in 41.9% continuing ecopipam versus 68.1% on placebo, a 53% relative relapse-risk reduction (HR, 0.50; P = .008). New analyses from ...

Countries such as the Solomon Islands and Fiji have pioneered mass drug administration for the disease. Sophie Cousins reports.